ALLK Stock Summary and Trading Ideas (Allakos | NASDAQ:ALLK)

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Allakos trades on the NASDAQ stock market under the symbol ALLK.

As of April 2, 2025, ALLK stock price climbed to $0.32 with 13,812,456 million shares trading.

ALLK has a beta of 2.09, meaning it tends to be more sensitive to market movements. ALLK has a correlation of 0.02 to the broad based SPY ETF.

ALLK has a market cap of $28.87 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ALLK traded as high as $8.73 and as low as $.22.

The top ETF exchange traded funds that ALLK belongs to (by Net Assets): VTI, VXF, IWC, ONEQ, FESM.

ALLK has underperformed the market in the last year with a return of -73.8%, while the SPY ETF gained +9.4%. In the last 3 month period, ALLK fell short of the market, returning -73.6%, while SPY returned -3.5%. However, in the most recent 2 weeks ALLK has outperformed the stock market by returning +25.4%, while SPY returned +0.8%.

ALLK support price is $.21 and resistance is $.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLK shares will trade within this expected range on the day.